Adjuvant Therapy of Cancer V

Edited by

Sydney E. Salmon, M.D.

Professor of Medicine
Section of Hematology and Oncology
Department of Internal Medicine
Director, Arizona Cancer Center
University of Arizona College of Medicine
Tucson, Arizona

G&S
Grune & Stratton, Inc.
Harcourt Brace Jovanovich, Publishers
Orlando San Diego New York London
San Francisco Tokyo Sydney Toronto
Contents

Preface xvii
Contributors xix

PART I Perspectives on Adjuvant Therapy

Drug Resistance and Adjuvant Therapy of Cancer
Sydney E. Salmon 3

The Effect of Dose Intensity in Adjuvant Chemotherapy
William M. Hryniuk, Gianni Bonadonna, and Pinuccia Valagussa 13

Adjuvant Radiotherapy in Chemosensitive Tumors
M. Tubiana, R. Arriagada, P. Carde, J.M. Cosset, and T. Le Chevalier 25

Current Status of Hyperthermia as an Adjuvant Therapeutic Modality
J. Robert Cassady 35

The Potential Role of Immunotherapy and Biological Therapy in the Adjuvant Therapy of Cancer
Evan M. Hersh 47

NCI/Extramural Clinical Trials of Interleukin-2 and Lymphokine-Activated Killer Cells for Cancer Treatment
Geoffrey R. Weiss, David H. Boldt, and Charles A. Coltman, Jr. 57

The Concept of Neoadjuvant Chemotherapy
Emil Frei III, John R. Clark, and Daniel Miller 67

PART II Head and Neck Cancer

The Role of Induction Chemotherapy in the Treatment of Advanced Head and Neck Cancer
Waun Ki Hong, Isaiah W. Dimery, Alan M. Kramer, Josephine Paredes, K. Thomas Robbins, and Bruce Campbell 79
Adjuvant Chemotherapy for Patients with Locally Advanced Head and Neck Cancer: RTOG and Wayne State University Experiences
Muhyi Al-Sarraf, Bruce Reading, Julie A. Kish, John F. Ensley, Efstatios Tapazoglou, Thomas Pajak, Victor Marcial, and George Laramore 89

Strategies for Improvements in Complete Response Rate with Adjuvant Combination Chemotherapy in Advanced Head and Neck Cancer (SCC of H&N)
John F. Ensley, Julie A. Kish, Efstatios Tapazoglou, and Muhyi Al-Sarraf 101

The Significance of Primary Site in Assessing Chemotherapy Response and Survival in Advanced Squamous Cell Carcinomas of the Head and Neck Treated with Initial Combination Chemotherapy without Cisplatin: Analyses at Nine Years
Bridget T. Hill and Len A. Price 111

Long Term Survival following Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck: A Ten Year Follow-Up
Daniel D. Karp, Charles W. Vaughan, Bernard Willett, Timothy Heeren, Nancy A. DiMartino, Miriam E. Vincent, Marie E. Picardi, and Waun Ki Hong 119

Neoadjuvant Chemotherapy and Irradiation for Stages III and IV Head and Neck Cancer: Is Radical Surgery Necessary?

Etoposide/Platinum Neoadjuvant Chemotherapy for Infants with Primary Malignant CNS Tumors
John J. Hutter, Jr., Paul S. Meltzer, and J. Robert Cassady 139

PART III  Lung Cancer

Adjuvant Chemotherapy Approaches in Non-Small Cell Lung Cancer
Richard J. Gralla, Mark G. Kris, Nael Martini, Laura V. Stampleman, and M. Thomasine Burke 147

Effectiveness of Adjuvant Chemotherapy in Operable Non-Small Cell Lung Cancer (NSCLC)
Joseph Ayoub, André Duranceau, Gilles Lorange, André Robidoux, James Hanley, Arthur Page, Alfred Joassin, Daniel Doyle, Edwin
PART IV  BREAST CANCER CHEMOTHERAPY: STAGES I-II

Milan Adjuvant Trials for Stage I-II Breast Cancer
  G. Bonadonna, P. Valagussa, M. Zambetti, R. Buzzoni, and A. Moliterni

Adjuvant Chemotherapy in Node-Negative Breast Cancer Patients:
  R. Jakesz, R. Kolb, G. Reiner, M. Schemper, H. Rainer, C. Dittrich,
  and A. Reiner

Adjuvant Chemotherapy for T1-2, N0, M0 Estrogen Receptor Negative
Breast Cancer: Preliminary Results of a Randomised Trial
  C.J. Williams, R.B. Buchanan, V. Hall, I. Taylor, T. Cooke, R.
  Nicholson, and K. Griffiths
Update of Swiss Adjuvant Trials with LMF and CMF in Operable Breast Cancer

_Hans-Jörg Senn and Regula Barett-Mahler, for the OSAKO- and SAKK Groups_ 243

Neoadjuvant Chemotherapy in Breast Cancer: As Single Perioperative Treatment and with Supplementary Long-Term Chemotherapy

_Roar Nissen-Meyer, Herman Høst, Kjell Kjellgren, Bror Månsson, and Torsten Norin_ 253

Breast Cancer Adjuvant Therapy Trials at the Arizona Cancer Center Using Adriamycin and Cyclophosphamide


Consistencies and Variations of Observations during Serial Analyses of a Trial of Adjuvant Chemotherapy in Breast Cancer

_G. Mathé, R. Plagne, V. Morice, and J.L. Misset, for the OncoFrance Breast Cancer Trial Group_ 271

**PART V BREAST CANCER STAGE II: CHEMOTHERAPY AND COMBINED MODALITY**

Long Term Results from NSABP Trials of Adjuvant Therapy for Breast Cancer

_Bernard Fisher, Carol K. Redmond, Norman Wolmark, and NSABP Investigators_ 283

Adjuvant Therapy for Breast Cancer: The Ludwig Breast Cancer Trials 1987

_Aron Goldhirsch and Richard D. Gelber, for the Ludwig Breast Cancer Study Group_ 297

The West Midlands Oncology Association Trials of Adjuvant Chemotherapy for Operable Breast Cancer


Adjuvant Chemotherapy Trials of Breast Cancer: A Progress Report from the Multicentre Cancer Chemotherapy Group (U.K.)

_Bridget T. Hill, Margaret F. Spittle, M.J. Ostrowski, K.D. MacRae, and Thelma D. Bates_ 319
Adjuvant Chemotherapy for Breast Carcinoma Using CMFVP versus CMF versus CMF-MER: The Nine Year Results for Patients with 1-3 Axillary Nodes

Adjuvant Systemic Risk Adapted Cytotoxic ± Tamoxifen Therapy in Women with Node Positive Breast Cancer
   Manfred Kaufmann, Walter Jonat, Hans Caffier, Rolf Kreienberg, Jörn Hilfrich, Ulrich Abel, Heinrich Maass, and Fred Kubli, for the Gynecological Adjuvant Breast Group (GABG) 337

Postsurgical Adjuvant Chemotherapy with or without Radiotherapy in Women with Breast Cancer and Positive Axillary Nodes: Progress Report of a Southeastern Cancer Study Group (SEG) Trial

The Effect of Post-Operative Radiotherapy on Adjuvant Chemotherapy for Stage II and III Breast Carcinoma
   Simon G. Tang, Fang-Jen Lin, and Ming-Shen Chen 357

Influence of the Sequencing of Chemotherapy and Radiation Therapy in Node-Negative Breast Cancer Patients Treated by Conservative Surgery and Radiation Therapy
   Stacey M. Gore, Steven E. Come, Katherine Griem, Mary Ann Rose, Abram Recht, Leslie E. Botnick, Christopher Rose, Geoffrey Beadle, Barbara Silver, I. Craig Henderson, and Jay R. Harris 365

PART VI: BREAST CANCER: HORMONAL THERAPY

The Role of Adjuvant Endocrine Therapy in Primary Breast Cancer
   Michael Baum, Alan J. Wilson, and Stephen R. Ebbs 377

Adjuvant Tamoxifen in Postmenopausal Women with Axillary Node Positive Breast Cancer: An Update
PART VII  BREAST CANCER STAGE III: CHEMOTHERAPY AND COMBINED MODALITY

Neo-Adjuvant Chemotherapy in the Conservative Management of Breast Cancer: A Study of 205 Patients
Claude Jacquillat, Marise Weil, Gérard Auclerc, Marie-Françoise Auclerc, David Khayat, and François Baillet 403

Breast Cancer Adjuvant Therapy Trials of M. D. Anderson Hospital: Results of Three Studies

Induction Chemotherapy for Stage III Primary Breast Cancer

Neo-Adjuvant Chemotherapy with Estrogenic Recruitment in Locally Advanced Breast Cancer
Paolo Pronzato, Pier Franco Conte, Angela Alama, Giuseppe Canavese, Giovanni Gardin, Angelo Nicolin, and Riccardo Rosso 429

PART VIII  BREAST CANCER: BIOLOGICAL FACTORS AND NEW ANALYTIC APPROACHES

The Importance of DNA Flowcytometry for Adjuvant Studies, in Particular in Node Negative Patients
G.H. Blijham, B. Schutte, M. Reynders, and L. Schouten 439

Long-Term Tamoxifen Therapy to Control Transplanted Human Breast Tumor Growth in Athymic Mice
Marco M. Gottardis, Mary K. Martin, and V. Craig Jordan 447

Time without Symptoms and Toxicity (TWiST): A Quality-of-Life-Oriented Endpoint to Evaluate Adjuvant Therapy
Richard D. Gelber, Aron Goldhirsch, Monica Castiglione, Karen Price, Mary Isley, and Alan Coates, for the Ludwig Breast Cancer Study Group 455

Meta-Analysis: Considerations of Its Worth and Its Limitations
Carol K. Redmond and Howard E. Rockette 467
PART IX  GASTROINTESTINAL CANCER

Adjuvant Therapy of Gastrointestinal Cancer
  John S. Macdonald 479

Neoadjuvant Chemoradiotherapy for Resectable Gastroesophageal Junction Adenocarcinoma
  Paul L. Weiden, Lucius D. Hill, Richard A. Kozarek, Mark D. Hafermann, John A. Ryan, Jr., and David J. Patterson, for the Virginia Mason Medical Center 497

Adjuvant Chemotherapy in Gastric Carcinoma
  R. Jakesz, C. Dittrich, J. Funovics, H. Rainer, M. Schemper, and R. Schiessell 507

Postoperative Immunochemotherapy with Mitomycin C, Futraful, and PSK for Curatively Resected Cases of Gastric Cancer
  Minoru Niimoto, Takao Hattori, Ryuichiro Tamada, Keizo Sugimachi, Kiyoshi Inokuchi, and Nobuya Ogawa 515

Confirmation by the Gastrointestinal Tumor Study Group that Survival Following Potentially Curative Resection of Pancreatic Cancer is Improved by Multidisciplinary Postoperative Therapy
  Harold O. Douglass, Jr., Donald M. Stablein, Martin H. Kalser, Donald W. Weaver, John C. Marsh, Paul V. Woolley, Howard W. Bruckner, Bernard Levin, Arthur H. Knowlton, and Seth M. Steinberg 525

Adjuvant Therapy in Carcinoma of the Colon: Five Year Results of NSABP Protocol C-01
  Norman Wolmark, Bernard Fisher, and Howard E. Rockette 531

The Australia and New Zealand Trial of Adjuvant Chemotherapy in Colon Cancer

Adjuvant Chemotherapy or Postoperative Radiation for Rectal Cancer: 5 Year Results of NSABP R-01
  Bernard Fisher, Norman Wolmark, Howard E. Rockette, and Carol K. Redmond 547
PART X  GENITOURINARY CANCER

Neoadjuvant and Adjuvant Chemotherapy for Urothelial Tract Tumors
Alan Yagoda 555

Adjuvant CISCA for Patients with High Risk Bladder Cancer
Christopher J. Logothetis, Douglas E. Johnson, Clayton Chong, Francisco H. Dexeus, Sheryl Ogden, Andrew C. von Eschenbach, and Alberto G. Ayala 565

Long-Term Control of Locally Advanced Transitional Cell Bladder Cancer (TCCB) by High-Dose Intensity, Circadian-Based Adjuvant Chemotherapy
Reinhard V. Roemeling, William J.M. Hrushesky, and Elwin E. Fraley 571

Adjuvant Medroxyprogesterone Acetate to Radical Nephrectomy in Renal Cell Carcinoma
Giorgio Pizzocaro, Luigi Piva, Giovanni di Fronzo, Alberto Cozzoli, Augusto Giongo, Silvano Minervini, Enrico Dormia, Umberto Fontanella, Alberto Zanollo, Giovanni Longo, and Augusto Maggioni 581

Early Stage Testis Cancer: The Testicular Cancer Intergroup Studies
Stephen D. Williams, Donald Stablein, Franco Muggia, Lawrence H. Einhorn, Richard Hahn, John P. Donohue, Kurt Brunner, William De Wys, David Crawford, Joseph Spaulding, Raymond B. Weiss, Robert Golbey, Edwin Mark Jacobs, and David Paulson 587

Long-Term Survival Rates in Stage I and Stage II Germ Cell Tumors of the Testis
Davor Vugrin, Amy Chen, and Polly Feigl 593

Stage II Nonseminomatous Testicular Tumours: Necessity and Extent of Adjuvant Chemotherapy
Joachim H. Hartlapp, Lothar Weißbach, and Bettina Horstmann-Dubral, for the Testicular Tumour Study Group Bonn 603

Adjuvant and Neoadjuvant Vincristine, Bleomycin, and Methotrexate (VBM) for Inguinal Metastases of Penile Cancer
Giorgio Pizzocaro and Luigi Piva 613
PART XI GYNECOLOGIC CANCER

Adjuvant Therapy in Gynecologic Cancer: The GOG Experience
   J. Tate Thigpen and Brian Bundy, for The Gynecologic Oncology
   Group 619

Stage III Optimal Disease Ovarian Cancer Relatively Resistant to
Adjuvant Cisplatin Chemotherapy In Vitro and In Vivo
   David S. Alberts, Nancy Mason-Liddil, Earl A. Surwit, Robert V.
   O'Toole, Richard Kronmal, Donald J. Slymen, and Sydney E.
   Salmon 629

Survival of Patients with Small Volume, Refractory Ovarian Carcinoma
Treated with Intraperitoneal Cisplatin-Based Chemotherapy
   Solomon Zimm, Maurie Markman, Stephen M. Cleary, Ian
   Abramson, William Lucas, and Stephen B. Howell 637

PART XII MELANOMA

Improvement in Disease-Free Survival of Melanoma Patients in
Conjunction with Serological Response in a Phase Ia/Ib SEG Trial
of Vaccinia Melanoma Oncolysate (VMO)
   Marc K. Wallack, Jerry A. Bash, Evelyn S. Darnell, and Alfred A.
   Bartolucci 647

Adjuvant Immunotherapy of M.D. Anderson Stage III-B Malignant
Melanoma with Newcastle Disease Viral Oncolysate
   Carl Plager, James M. Bowen, Claudia J. Fenoglio, Nicholas E.J.
   Papadopoulos, Lee Murray, Sant P. Chawla, Robert S. Benjamin,
   H.E. Savage, R.D. Rossen, and E.M. Hersh 657

Randomized Trial of BCG ± Vitamin A for Stages I and II Cutaneous
Malignant Melanoma
   Frank L. Meyskens, Jr., Ann E. Booth, Paula Goff, and Thomas E.
   Moon 665

Adjuvant Perfusion Chemotherapy of Cutaneous Malignant Melanoma:
With Minimum 5 Year Follow-Up
   Vishram B. Rege, Louis A. Leone, Clarence H. Soderberg, George V.
   Coleman, Henry J. Robidoux, Ruben Fijman, Jeanne Brown, and
   Cyrus R. Mehta 671
In Vitro Bioassay for Testing Perfusate Toxicity in Isolation Perfusion for Extremity Melanoma

K.H. Link, W. Kuehn, K.R. Aigner, and H. Voigt 679

PART XIII SARCOMA

A Randomized Prospective Trial of Adjuvant Chemotherapy for Osteosarcoma

Frederick R. Eilber, Armando E. Giuliano, Jeffrey Eckardt, Karen Patterson, H. Stephens Moseley, and James Goodnight, Jr. 691

Preoperative Intra-Arterial Cisplatin and Limb-Salvage Surgery for Patients with High-Grade Osteosarcoma of the Extremities

Sant P. Chawla, Robert S. Benjamin, Norman Jaffe, Cesar H. Carrasco, A. Kevin Raymond, Alberto Ayala, Sidney Wallace, Terri Armen, Nicholas E.J. Papadopoulos, Carl Plager, and John A. Murray 701

Neoadjuvant Chemotherapy for Localized Osteosarcoma of the Extremities: Experience Related to 112 Cases Treated between March 1983 and June 1986

Piero Picci, Gaetano Bacci, Rodolfo Capanna, Mario Mercuri, Nicola Baldini, Giovanni Pignatti, Pietro Ruggieri, Roberto Biagini, Maddalena Avella, Mario Campanacci, Enrico Madon, Adalberto Brach del Prever, Guido Paolucci, and Antonia Mancini 711

Postoperative Adjuvant Chemotherapy (Adriamycin) in High Grade Extremity Soft Tissue Sarcoma: A Randomized Prospective Trial

Frederick R. Eilber, Armando E. Giuliano, James F. Huth, and Donald L. Morton 719

A Preliminary Analysis of a Randomized Intergroup (SWOG, ECOG, CALGB, NCOG) Trial of Adjuvant Doxorubicin for Soft Tissue Sarcomas

Karen Antman, David Amato, Michael Pilepich, Harvey Lerner, Stanley Balcerzak, Ernest Borden, and Laurence Baker 725

The Importance of Combination Chemotherapy for Adjuvant Treatment of High-Risk Patients with Soft-Tissue Sarcomas of the Extremities

Robert S. Benjamin, Terenij O. Terjanian, Claudia J. Fenoglio, Howard T. Barkley, Harry L. Evans, William K. Murphy, and Richard G. Martin 735
Prospective Randomized Trial Examining the Cardiac Toxicity of Adjuvant Doxorubicin in High Grade Extremity Sarcomas
Murray F. Brennan, Claudia Friedrich, Lois Almadrones, and Gordon Magill

PART XIV  LYMPHOMA

Chemotherapy with or without Adjuvant Radiotherapy for Stage I and II Large Cell Lymphoma
Stephen E. Jones, Thomas P. Miller, Joseph M. Connors, and Denise Roe

Chemotherapy Plus Radiotherapy for Hodgkin’s Disease: Clinical Stages IA and IIA
Jean-Marie Andrieu, Philippe Casassus, Bernard Desablens, Jean-Luc Harousseau, Jean Briere, Jean-Marc Tourani, Annick Lemevel, Norbert Ifrah, Max Dana, Yvan Coscas, and Claude Jacquillat

Two Cycles of MOPP as Adjuvant Therapy for Stage I-II Hodgkin’s Disease
Frederick B. Hagemeister, Lillian M. Fuller, William S. Velasquez, Peter McLaughlin, and Fernando Cabanillas

Adjuvant Radiotherapy for Advanced Hodgkin’s Disease: 15 Year Survival Data

PART XV  CONFERENCE SUMMARY

Conference Summary
Lawrence H. Einhorn

Index